Last updated: March 2026
Hexarelin is the most potent synthetic growth hormone-releasing peptide (GHRP) known — a six-amino-acid chain that activates the ghrelin receptor with exceptional affinity, producing the largest acute GH pulses of any GHRP class peptide in preclinical and early clinical research.
Hexarelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor activated by the endogenous hunger hormone ghrelin. This triggers a strong, acute GH pulse from somatotroph cells in the anterior pituitary, amplified further when combined with a GHRH analog.
Hexarelin binds GHS-R1a with higher affinity than ghrelin itself due to its modified amino acid structure (D-2-methyltryptophan). This produces maximal GH pulse amplitude exceeding GHRP-2 and GHRP-6. A single 2 mcg/kg IV dose raises GH by 6-8 ng/mL in healthy adults (early clinical data).
Like all GHRPs, hexarelin works via two complementary pathways: direct pituitary stimulation via GHS-R1a, and indirect amplification through hypothalamic GHRH release. Combining hexarelin with a GHRH analog (CJC-1295, sermorelin) creates a synergistic GH pulse substantially larger than either alone.
Hexarelin's high receptor efficacy accelerates GHS-R1a downregulation. Continuous daily use produces measurable GH blunting within 1-2 weeks, with significant attenuation by week 4. Intermittent protocols (5 days on / 2 days off, or cycling every 4-6 weeks) are used in research to preserve receptor sensitivity.
Hexarelin binds the CD36 receptor on cardiomyocytes independently of GH release, producing cardioprotective effects in animal models. Post-infarct cardiac function improved in rodent studies. This non-GH receptor pathway is unique to hexarelin among GHRPs and represents an area of active preclinical research (animal data only).
Hexarelin and Ipamorelin are both GHS-R1a agonists, but they have meaningfully different profiles in potency, selectivity, and side effect burden. Understanding these distinctions is key to choosing between them.
Hexarelin's structural modification — D-2-methyltryptophan in place of the standard residue — gives it substantially higher GHS-R1a binding affinity than ipamorelin. The resulting acute GH peak is approximately 3–5× higher than an equivalent Ipamorelin dose. For sheer GH amplitude, hexarelin has no peer in the GHRP class.
Ipamorelin earned its "selective GHRP" designation specifically because it doesn't meaningfully raise cortisol or prolactin at effective GH-releasing doses (Raun 1998). Hexarelin lacks this selectivity — it activates pituitary pathways that release both cortisol and prolactin alongside GH. For protocols focused on GH benefits without adrenal loading, this is a significant drawback relative to Ipamorelin.
Hexarelin's most scientifically interesting distinguishing feature is its ability to bind the CD36 receptor on cardiac muscle cells — completely independent of GH secretion. In animal post-infarct models, hexarelin reduced cardiomyocyte apoptosis and improved contractile function via this direct receptor pathway. This cardioprotective effect persists even in pituitary-deficient or hypophysectomized animals, confirming it has nothing to do with GH release. Human data on this property is limited, but the mechanism is well-characterized preclinically.
High potency comes with a cost: hexarelin downregulates the GHS-R1a receptor faster than GHRP-2, GHRP-6, or Ipamorelin. Continuous daily use can produce measurable blunting of GH response within 1–2 weeks. Without cycling, the window of peak efficacy is short. This makes disciplined cycling more critical with hexarelin than with any other GHRP class compound.
Data from preclinical animal studies and early-phase human clinical research on hexarelin. All human data from small trials; treat as preliminary.
Research and reconstitution supplies for peptide protocols.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and research purposes only. It is not medical advice. Hexarelin is not FDA approved for human use. Research data cited includes preclinical animal studies and small early-phase human trials. Always consult a qualified physician before considering any peptide compound.